Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Psoriasis 1Periodic Fevers Syndrome 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 454Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has results × secukinumab × Clear all
NCT01961609 2019-03-18

SIGNATURE

Novartis

Phase 3 Completed
235 enrolled 23 charts

Psoriasis

NCT02911857 2018-08-20

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

Novartis

Phase 3 Completed
4 enrolled 7 charts

Periodic Fevers Syndrome

NCT01350804 2016-05-23

NURTURE 1

Novartis

Phase 3 Completed
551 enrolled 19 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡